Cargando…

AI-powered discovery of a novel p53-Y220C reactivator

INTRODUCTION: The p53-Y220C mutation is one of the most common mutations that play a major role in cancer progression. METHODS: In this study, we applied artificial intelligence (AI)-powered virtual screening to identify small-molecule compounds that specifically restore the wild-type p53 conformati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shan, Chai, Dafei, Wang, Xu, Neeli, Praveen, Yu, Xinfang, Davtyan, Aram, Young, Ken, Li, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430779/
https://www.ncbi.nlm.nih.gov/pubmed/37593097
http://dx.doi.org/10.3389/fonc.2023.1229696
_version_ 1785091044844503040
author Zhou, Shan
Chai, Dafei
Wang, Xu
Neeli, Praveen
Yu, Xinfang
Davtyan, Aram
Young, Ken
Li, Yong
author_facet Zhou, Shan
Chai, Dafei
Wang, Xu
Neeli, Praveen
Yu, Xinfang
Davtyan, Aram
Young, Ken
Li, Yong
author_sort Zhou, Shan
collection PubMed
description INTRODUCTION: The p53-Y220C mutation is one of the most common mutations that play a major role in cancer progression. METHODS: In this study, we applied artificial intelligence (AI)-powered virtual screening to identify small-molecule compounds that specifically restore the wild-type p53 conformation from p53-Y220C. From 10 million compounds, the AI algorithm selected a chemically diverse set of 83 high-scoring hits, which were subjected to several experimental assays using cell lines with different p53 mutations. RESULTS: We identified one compound, H3, that preferentially killed cells with the p53-Y220C mutation compared to cells with other p53 mutations. H3 increased the amount of folded mutant protein with wild-type p53 conformation, restored its transcriptional functions, and caused cell cycle arrest and apoptosis. Furthermore, H3 reduced tumorigenesis in a mouse xenograft model with p53-Y220C-positive cells. CONCLUSION: AI enabled the discovery of the H3 compound that selectively reactivates the p53-Y220C mutant and inhibits tumor development in mice.
format Online
Article
Text
id pubmed-10430779
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104307792023-08-17 AI-powered discovery of a novel p53-Y220C reactivator Zhou, Shan Chai, Dafei Wang, Xu Neeli, Praveen Yu, Xinfang Davtyan, Aram Young, Ken Li, Yong Front Oncol Oncology INTRODUCTION: The p53-Y220C mutation is one of the most common mutations that play a major role in cancer progression. METHODS: In this study, we applied artificial intelligence (AI)-powered virtual screening to identify small-molecule compounds that specifically restore the wild-type p53 conformation from p53-Y220C. From 10 million compounds, the AI algorithm selected a chemically diverse set of 83 high-scoring hits, which were subjected to several experimental assays using cell lines with different p53 mutations. RESULTS: We identified one compound, H3, that preferentially killed cells with the p53-Y220C mutation compared to cells with other p53 mutations. H3 increased the amount of folded mutant protein with wild-type p53 conformation, restored its transcriptional functions, and caused cell cycle arrest and apoptosis. Furthermore, H3 reduced tumorigenesis in a mouse xenograft model with p53-Y220C-positive cells. CONCLUSION: AI enabled the discovery of the H3 compound that selectively reactivates the p53-Y220C mutant and inhibits tumor development in mice. Frontiers Media S.A. 2023-08-01 /pmc/articles/PMC10430779/ /pubmed/37593097 http://dx.doi.org/10.3389/fonc.2023.1229696 Text en Copyright © 2023 Zhou, Chai, Wang, Neeli, Yu, Davtyan, Young and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhou, Shan
Chai, Dafei
Wang, Xu
Neeli, Praveen
Yu, Xinfang
Davtyan, Aram
Young, Ken
Li, Yong
AI-powered discovery of a novel p53-Y220C reactivator
title AI-powered discovery of a novel p53-Y220C reactivator
title_full AI-powered discovery of a novel p53-Y220C reactivator
title_fullStr AI-powered discovery of a novel p53-Y220C reactivator
title_full_unstemmed AI-powered discovery of a novel p53-Y220C reactivator
title_short AI-powered discovery of a novel p53-Y220C reactivator
title_sort ai-powered discovery of a novel p53-y220c reactivator
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430779/
https://www.ncbi.nlm.nih.gov/pubmed/37593097
http://dx.doi.org/10.3389/fonc.2023.1229696
work_keys_str_mv AT zhoushan aipowereddiscoveryofanovelp53y220creactivator
AT chaidafei aipowereddiscoveryofanovelp53y220creactivator
AT wangxu aipowereddiscoveryofanovelp53y220creactivator
AT neelipraveen aipowereddiscoveryofanovelp53y220creactivator
AT yuxinfang aipowereddiscoveryofanovelp53y220creactivator
AT davtyanaram aipowereddiscoveryofanovelp53y220creactivator
AT youngken aipowereddiscoveryofanovelp53y220creactivator
AT liyong aipowereddiscoveryofanovelp53y220creactivator